secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2026-08-03T12:03:40+00:00
Accession:  0001193125-26-329570
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics reports Q2 net loss of $20.2M; modifies RESTORE-FA trial, delays FECD data
--------------------------------------------------------------------------------

- Net loss of $20.2M for Q2 2026; cash and securities of $207.4M at quarter-end.
- RESTORE-FA trial modified: 12-week cohort at 1 mpk, primary endpoint endogenous FXN protein change; data expected Q1 2027.
- Phase 1 MAD trial of DT-818 in DM1 initiated; data expected in 2027.
- Phase 2 FECD trial of DT-168 delayed to 2027 due to supply issue with eye droppers.
- Registrational plan update expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000119312526329570/0001193125-26-329570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000119312526329570/dsgn-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-329570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer